- No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other malignancy that does not carry a worse prognosis than advanced esophageal cancer

- No other serious underlying medical condition that would preclude study

- No other concurrent disease that would preclude study

- No psychiatric illness or other significant mental impairment that would preclude study

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior chemotherapy

Endocrine therapy:

- See Disease Characteristics

Radiotherapy:

- See Disease Characteristics

- At least 2 weeks since prior radiotherapy and recovered

- No prior radiotherapy to the pelvis

Surgery:

- See Disease Characteristics

- Not specified

Other:

- No concurrent phenytoin or phenobarbital

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

David H. Ilson, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Federal Government

Study ID:

01-123

NCT ID:

NCT00030862

Start Date:

October 2001

Completion Date:

December 2003

Related Keywords:

Esophageal Cancer

stage II esophageal cancer

stage III esophageal cancer

stage IV esophageal cancer

squamous cell carcinoma of the esophagus

adenocarcinoma of the esophagus

Esophageal Diseases

Esophageal Neoplasms

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.